Title
|
|
|
|
Added diagnostic value of cerebrospinal fluid biomarkers for differential dementia diagnosis in an autopsy-confirmed cohort
|
|
Author
|
|
|
|
|
|
Abstract
|
|
|
|
Background: Differential dementia diagnosis remains a challenge due to overlap of clinical profiles, which often results in diagnostic doubt. Objective: Determine the added diagnostic value of cerebrospinal fluid (CSF) biomarkers for differential dementia diagnosis as compared to autopsy-confirmed diagnosis. Methods: Seventy-one dementia patients with autopsy-confirmed diagnoses were included in this study. All neuropathological diagnoses were established according to standard neuropathological criteria and consisted of Alzheimer's disease (AD) or other dementias (NONAD). CSF levels of A beta(1-42), T-tau, and P-tau(181) were determined and interpreted based on the IWG-2 and NIA-AA criteria, separately. A panel of three neurologists experienced with dementia made clinical consensus dementia diagnoses. Clinical and CSF biomarker diagnoses were compared to the autopsy-confirmed diagnoses. Results: Forty-two patients (59%) had autopsy-confirmed AD, whereas 29 patients (41%) had autopsy-confirmed NONAD. Of the 24 patients with an ambiguous clinical dementia diagnosis, a correct diagnosis would have been established in 67% of the cases applying CSF biomarkers in the context of the IWG-2 or the NIA-AA criteria respectively. Conclusion: AD CSF biomarkers have an added diagnostic value in differential dementia diagnosis and can help establishing a correct dementia diagnosis in case of ambiguous clinical dementia diagnoses. |
|
|
Language
|
|
|
|
English
|
|
Source (journal)
|
|
|
|
Journal of Alzheimer's disease. - -
|
|
Publication
|
|
|
|
2018
|
|
ISSN
|
|
|
|
1387-2877
1875-8908
[Electronic]
|
|
DOI
|
|
|
|
10.3233/JAD-170927
|
|
Volume/pages
|
|
|
|
63
:1
(2018)
, p. 373-381
|
|
ISI
|
|
|
|
000430016100034
|
|
Pubmed ID
|
|
|
|
29614653
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|